Dasatinib or ABL second-generation TKI used in combination with COG-based chemotherapy or EsPhALL is also an effective targeted treatment strategy in pediatric Ph + ALL [75]. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.